Announcement of Our Investment in PulmoGate
2026.11.18
Beyond Next Ventures Inc. (Chuo-ku, Tokyo; Founder CEO / Managing Partner: Tsuyoshi Ito; hereinafter “Beyond Next Ventures”) is pleased to announce its investment as the lead investor in the seed round of PulmoGate Inc. (Nagoya, Aichi; Representative Director and CEO: Tomo Tominaga, hereinafter “PulmoGate”).
PulmoGate raised a total of approximately JPY 330 million in this round.
About PulmoGate
PulmoGate is a medical AI startup originating from Nagoya University that aims to address clinical challenges in interstitial lung disease (ILD)—from diagnosis and treatment to rehabilitation—using AI and digital technologies.
The company is developing a platform that supports remote multidisciplinary discussion (MDD) among interstitial lung disease specialists. By providing second opinions based on expert reviews of diagnosis and treatment, the platform aims to support attending physicians’ decision-making and help patients make informed treatment choices.
Building on its remote MDD platform, PulmoGate is also developing technologies that support patients throughout the care journey—from diagnosis and treatment to at-home monitoring and rehabilitation—including diagnostic AI and AI to support treatment planning.
The diagnostic AI, AI to support treatment planning, and technologies supporting at-home monitoring and rehabilitation are currently in the research and development stage and are not approved as medical devices.
PulmoGate Website: https://pulmogate.com/
Background of the Investment
ILD is a group of diseases that cause inflammation and fibrosis of the lungs, and it is the 11th leading cause of death in Japan.[1] The five-year survival rate is 59.9% for ILD overall and 32.1% for idiopathic pulmonary fibrosis (IPF), its representative subtype,[2] and lung fibrosis, once advanced, is difficult to reverse. Idiopathic interstitial pneumonias, including IPF, are designated as intractable diseases in Japan. A European study also reported a median diagnostic delay of 2.1 years for IPF, with 41% of patients having been misdiagnosed before receiving a definitive diagnosis.[3]
Because the causes, disease types, and rates of progression vary from patient to patient, ILD requires specialized expertise for accurate diagnosis and treatment planning. Accurate diagnosis often requires multidisciplinary discussion (MDD), in which pulmonologists, radiologists, and, where needed, pathologists review a case together, as recommended in domestic and international guidelines. However, relatively few medical institutions have all of these specialists available in-house, limiting access to appropriate diagnosis, prognostic assessment, medication selection, and pulmonary rehabilitation.
To address these challenges, PulmoGate is developing remote MDD-based second-opinion support and technologies that connect diagnosis and treatment with at-home monitoring and rehabilitation, including diagnostic AI based on large-scale clinical registry data. We decided to invest in PulmoGate based on the significance of these clinical challenges, the strength of its clinically grounded AI, and the execution capabilities of its management team, which combines experience in building and selling a business, medical AI research and development, and clinical expertise in ILD.
Going forward, we will leverage our expertise and network of corporate partners, investors, and executive talent to support PulmoGate in advancing its research and development (R&D), regulatory strategy, business development, and organizational capabilities.
For more details about our investment in PulmoGate, please read this article by our investment team.
If Only We Had Diagnosed It Earlier — Why We Invested in PulmoGate
https://beyondnextventures.com/media/pulmogate
[1] Rank based on Japan’s 2023 Vital Statistics (final figures).
Source: https://www.jstage.jst.go.jp/article/naika/113/9/113_1712/_pdf
[2] A nationwide claims-database study using data from 2015 to 2023 reported five-year survival rates of 59.9% for ILD overall and 32.1% for IPF.
Source: https://doi.org/10.1016/j.resinv.2026.101367
[3] In a Danish multicenter cohort of 204 patients with IPF, the median time from symptom onset to diagnosis was 2.1 years, and 41% reported misdiagnosis of respiratory symptoms.
Source: https://doi.org/10.1186/s12931-019-1076-0
Comments from Beyond Next Ventures
Katsuya Hashizume, Executive Officer, Partner and Head of Investment Division
Interstitial lung disease is difficult to diagnose, and the field has long faced a structural challenge: it is difficult to make accurate diagnoses and appropriate treatment decisions without specialized expertise. As a result, many patients remain undiagnosed or misdiagnosed for extended periods. This is a global challenge, not one limited to Japan, and improving diagnosis could directly improve patient outcomes.
PulmoGate is taking a unique approach to connecting the diagnosis, treatment, and rehabilitation of interstitial lung disease, built on high-quality clinical data accumulated by Nagoya University together with medical institutions across Japan. CMO Dr. Taiki Furukawa is one of Japan’s leading specialists in this field, and CEO Tomo Tominaga built a preventive healthcare business from the ground up, grew it, and led it through its sale. We see significant potential in this team, which combines scientific depth with the ability to drive business forward.
We have supported PulmoGate since it began exploring the commercialization of its research outcomes, including business planning and the formation of its management team. We will continue working closely with the PulmoGate team to help bring new medical options to patients.
About Beyond Next Ventures Inc.
Creating the beyond next society; enabling exceptional people solving global challenges.
Beyond Next Ventures is a deep-tech venture capital firm dedicated to translating scientific breakthroughs into real-world impact and building a virtuous cycle in which the value created fuels the next wave of innovation. We manage JPY 48 billion (approximately US$320 million) in funds focused on deep-tech startups. Through our proprietary company creation capabilities, executive talent matching, and TECHNIUM Global Conference that convenes key stakeholders from Japan and around the world, we strengthen a deep-tech innovation ecosystem and accelerate the commercialization of research outcomes in collaboration with industry, academia, and government.
- Head Office: Nihonbashi Honcho Showa-dori Building 3F, 3-7-2 Nihonbashi-honcho, Chuo-ku, Tokyo
- Subsidiary: Galaxy-Wework, 43, Residency Road, Shanthala Nagar Ashok Nagar, Bengaluru, Karnataka, India – 560025
- Representative: Founder CEO / Managing Partner Tsuyoshi Ito, Managing Director / General Partner Kengo Ueha
- Established: August 2014
- Business: Investment and growth support for deep tech startups in Japan and India, support for the commercialization of research seeds, cultivation and formation of management talent and teams, operation of shared wet labs, etc.
- Website: https://beyondnextventures.com